Home Ingredients 4-Hydroxy-L-Isoleucine
Metabolic HealthAthletic Performance

4-Hydroxy-L-Isoleucine

Trigonella foenum-graecum
Evidence Level
Limited
3 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

4-Hydroxy-L-Isoleucine (4-OH-Ile) is a non-proteinogenic amino acid found in fenugreek (Trigonella foenum-graecum) seeds at roughly 0.5–1% of seed weight. It is the leading candidate molecule behind fenugreek's traditional anti-diabetic reputation, acting as a glucose-dependent insulinotropic agent — meaning it stimulates pancreatic beta-cell insulin secretion only in the presence of elevated blood glucose, reducing the theoretical risk of hypoglycemia compared with broad insulin secretagogues. NNB Nutrition and several specialty ingredient suppliers produce standardized 4-hydroxy-L-isoleucine extracts targeting glycemic control and post-workout glucose disposal applications, although robust standalone human evidence remains limited.

Studied Dose Standalone 4-OH-Ile human data is limited; preclinical doses range 18–50 mg/kg in rats. Fenugreek seed extracts standardized for 4-OH-Ile are typically used at 300–600 mg/day in humans, providing variable amounts of the active amino acid.
Active Compound 4-Hydroxy-L-Isoleucine — non-proteinogenic branched-chain amino acid from fenugreek seeds; available as standardized extracts (e.g., NNB Nutrition) at varying purities

Benefits

Glucose-dependent insulin secretion support

Preclinical and human studies suggest 4-hydroxy-L-isoleucine stimulates insulin secretion only in the presence of elevated blood glucose. This glucose-dependence reduces the theoretical risk of supplement-induced hypoglycemia compared with non-selective insulin secretagogues.

Supported by Trial 1, Trial 2

Support for post-meal glycemic control

By enhancing insulin response selectively when glucose is high, 4-OH-Ile is positioned to support post-prandial glycemic control in individuals with normal or impaired glucose tolerance, complementing dietary carbohydrate management strategies.

Supported by Trial 2, Trial 1

Potential role in post-workout carbohydrate handling

The glucose-dependent insulinotropic action makes 4-OH-Ile a candidate ingredient in post-workout glucose-disposal formulas aiming to enhance carbohydrate uptake into muscle, although direct human ergogenic data is limited and effects should be expected to be modest.

Supported by Trial 1, Trial 2

Adjunct to fenugreek-based metabolic formulas

As the principal insulinotropic constituent of fenugreek seeds, 4-OH-Ile contributes to the metabolic effects of standardized fenugreek extracts used in glycemic-support products, alongside fiber components and trigonelline.

Supported by Trial 1

Mechanism of action

1

Direct stimulation of pancreatic beta-cell insulin release

Isolated islet and animal pancreas studies show 4-OH-Ile directly enhances insulin secretion from pancreatic beta-cells. The effect depends on extracellular glucose concentration — minimal at low glucose and pronounced at elevated glucose — distinguishing it from non-selective secretagogues like sulfonylureas.

2

Activation of insulin signalling in peripheral tissues

4-OH-Ile has been reported to activate insulin signalling pathways in rat liver and skeletal muscle (insulin receptor substrate, PI3K, Akt), supporting peripheral insulin sensitization in addition to its insulinotropic action at the beta-cell.

3

Improvement in glucose tolerance

Animal and isolated tissue work shows 4-OH-Ile improves glucose tolerance in normal and insulin-resistant models. The combination of glucose-dependent insulin secretion and improved peripheral signalling provides a coherent mechanistic basis for fenugreek's metabolic effects.

Clinical trials

1
4-Hydroxyisoleucine as a Novel Insulin Secretion Potentiator

Landmark characterization of 4-hydroxyisoleucine as a novel amino acid potentiator of insulin secretion. Experiments in isolated rat and human pancreatic islets evaluating glucose-dependent insulin release. Published in Diabetes.

Isolated rat and human pancreatic islets; preclinical mechanism trial.

4-Hydroxyisoleucine stimulated insulin secretion in a glucose-dependent manner in both rat and human islets, with minimal effect at low glucose and pronounced effect at elevated glucose. Identified 4-OH-Ile as the principal insulinotropic constituent of fenugreek seeds.

2
4-Hydroxyisoleucine Insulinotropic and Antidiabetic Properties

Experimental study of 4-hydroxyisoleucine's insulinotropic and antidiabetic actions in normal and diabetic rats. Published in American Journal of Physiology.

Normal and diabetic rat models; controlled experimental design.

4-Hydroxyisoleucine produced glucose-dependent insulin release and improved glucose tolerance in diabetic rats. Activity was preserved across normal and diabetic states, supporting it as the lead candidate antidiabetic molecule from fenugreek.

3
4-Hydroxyisoleucine (ID-1101) Activates Insulin Signaling in Rat

Mechanistic study evaluating the effects of synthetic 4-hydroxyisoleucine (ID-1101) on insulin signalling pathways in rat tissues. Published in American Journal of Physiology — Endocrinology and Metabolism.

Rat model; mechanistic experimental design.

4-Hydroxyisoleucine activated insulin signalling pathways including insulin receptor substrate-1 phosphorylation and downstream PI3K/Akt cascade in rat tissues, supporting peripheral insulin sensitization as a complementary mechanism alongside its insulinotropic action.

Side effects and drug interactions

Common Potential side effects

Limited standalone human safety data; most safety information derives from fenugreek extract trials.
Possible GI symptoms (mild diarrhea, bloating) reported with fenugreek seed products.
Distinctive maple-syrup odor of fenugreek may appear in sweat or urine.
Theoretical risk of hypoglycemia in combination with strong antidiabetic drugs despite glucose-dependent action.
Pregnancy: fenugreek has uterotonic effects; 4-OH-Ile-containing products should be avoided in pregnancy.

Important Drug interactions

Insulin and sulfonylureas — additive insulin/glucose-lowering effect; monitor closely.
Other antidiabetic agents (metformin, GLP-1 agonists, SGLT2 inhibitors) — monitor glycemic control when combining.
Warfarin — fenugreek seed has anticoagulant constituents; coordinate INR monitoring.
MAO inhibitors — theoretical interaction with branched-chain amino acid metabolism; use cautiously.

More Metabolic Health Ingredients

Cardiovascular
Niacin
Niacin, or vitamin B3, is a vital nutrient that supports energy production by serving as a…
Muscle & Recovery
Magnesium
Magnesium is the fourth most abundant mineral in the body and a cofactor for over 300 enzy…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Metabolic Health
Psyllium Husk (Plantago ovata)
Psyllium husk is the soluble fiber derived from the seed husks of Plantago ovata — the mos…

Explore Other Ingredients

Athletic Performance
Senactiv®
Senactiv® (formerly ActiGin®) is NuLiv Science's patented senolytic sportsceutical — a hig…
Athletic Performance
L-Carnitine
L-Carnitine is a naturally-occurring amino acid derivative essential for fatty acid metabo…
Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body and the primary metabolic fuel for…

Frequently asked questions about 4-Hydroxy-L-Isoleucine

What is the recommended dosage of 4-Hydroxy-L-Isoleucine?

The clinically studied dose for 4-Hydroxy-L-Isoleucine is Standalone 4-OH-Ile human data is limited; preclinical doses range 18–50 mg/kg in rats. Fenugreek seed extracts standardized for 4-OH-Ile are typically used at 300–600 mg/day in humans, providing variable amounts of the active amino acid.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is 4-Hydroxy-L-Isoleucine used for?

4-Hydroxy-L-Isoleucine is studied for glucose-dependent insulin secretion support, support for post-meal glycemic control, potential role in post-workout carbohydrate handling. Preclinical and human studies suggest 4-hydroxy-L-isoleucine stimulates insulin secretion only in the presence of elevated blood glucose.

Are there side effects from taking 4-Hydroxy-L-Isoleucine?

Reported potential side effects may include: Limited standalone human safety data; most safety information derives from fenugreek extract trials. Possible GI symptoms (mild diarrhea, bloating) reported with fenugreek seed products. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does 4-Hydroxy-L-Isoleucine interact with medications?

Known drug interactions may include: Insulin and sulfonylureas — additive insulin/glucose-lowering effect; monitor closely. Other antidiabetic agents (metformin, GLP-1 agonists, SGLT2 inhibitors) — monitor glycemic control when combining. Consult a pharmacist or healthcare provider if you take prescription medications.

Is 4-Hydroxy-L-Isoleucine good for metabolic health?

Yes, 4-Hydroxy-L-Isoleucine is researched for Metabolic Health support. As the principal insulinotropic constituent of fenugreek seeds, 4-OH-Ile contributes to the metabolic effects of standardized fenugreek extracts used in glycemic-support products, alongside fiber components and trigonelline.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, Gross R, Roye M, Leconte A, Gomis R, Ribes G. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes. 1998;47(2):206-10. doi: 10.2337/diab.47.2.206.PubMedUsed to support: Foundational characterization — 4-hydroxyisoleucine stimulated insulin secretion in a glucose-dependent manner in isolated rat and human pancreatic islets, identifying it as the principal insulinotropic constituent of fenugreek seeds.
  2. Broca C, Gross R, Petit P, Sauvaire Y, Manteghetti M, Tournier M, Masiello P, Gomis R, Ribes G. 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol. 1999;277(4):E617-23. doi: 10.1152/ajpendo.1999.277.4.E617.PubMedUsed to support: Experimental rat study — 4-hydroxyisoleucine produced glucose-dependent insulin release and improved glucose tolerance in diabetic rat models, supporting its insulinotropic and antidiabetic properties.
  3. Broca C, Breil V, Cruciani-Guglielmacci C, Manteghetti M, Rouault C, Derouet M, Rizkalla S, Pau B, Petit P, Ribes G, Ktorza A, Gross R, Reach G, Taouis M. Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab. 2004;287(3):E463-71. doi: 10.1152/ajpendo.00163.2003.PubMedUsed to support: Mechanistic rat study — synthetic 4-hydroxyisoleucine (ID-1101) activated insulin signalling pathways (IRS-1, PI3K, Akt) in rat tissues, supporting peripheral insulin sensitization as a complementary mechanism to its insulinotropic action.